Edoxaban for TIA and Acute Minor Stroke

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 3700 participants.

Also called NCT02221102

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 3,700 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02221102
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02221102. Randomized; triple masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2015-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Edoxaban for TIA and Acute Minor Stroke
Condition
Ischemia
Condition
Stroke
Condition
Cerebral Infarction
Intervention (Drug)
Aspirin
Intervention (Drug)
edoxaban
Intervention (Drug)
placebo
Lead sponsor
Xijing Hospital (class: other)

Record details

Record id
cardio:ct-nct02221102
Content hash
d710117e2aa45106368bc0b1f3ce0aeb2823c6ca65f97c5336669ef3b1f9f59b